NCT01471470View on ClinicalTrials.gov

Efficacy of Docetaxel, Capecitabine, Cisplatin, and Bevacizumab in Patients With Unresectable Advanced Gastric Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

31

Participants

Timeline

Start Date

July 31, 2010

Primary Completion Date

December 31, 2017

Study Completion Date

July 31, 2018

Conditions
Advanced Gastric Cancer
Interventions
DRUG

Docetaxel, Capecitabine, Cisplatin, Bevacizumab

Bevacizumab 7.5mg/kg IV (D1) Docetaxel 60 mg/m2 IV (D1) Cisplatin 60 mg/m2 IV (D1) Xeloda 1,875 mg/m2/day/bid PO (D1-D14)

Trial Locations (1)

138-736

Asan Medical Center, Seoul

Sponsors
All Listed Sponsors
collaborator

Roche Pharma AG

INDUSTRY

lead

Asan Medical Center

OTHER

NCT01471470 - Efficacy of Docetaxel, Capecitabine, Cisplatin, and Bevacizumab in Patients With Unresectable Advanced Gastric Cancer | Biotech Hunter | Biotech Hunter